Dr. William B. Nelson, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 722
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Minnesota Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MN license 41514
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Regions Hospital Saint PAul, MN
- Lakeview Memorial Hospital Stillwater, MN
- Hudson Hospital Hudson, WI
- Amery Hospital & Clinic Amery, WI
- Westfields Hospital and Clinic New Richmond, WI
Medical groups
- Group Health Inc (1,638 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 722
- Services billed
- 1,029
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 381 | 366 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 98 | 98 |
| Established patient office or other outpatient visit, 30-39 minutes | 47 | 44 |
| Insertion of needle into vein for collection of blood sample | 46 | 35 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 41 | 41 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | 37 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 36 | 36 |
| Mri scan of heart before and after contrast | 30 | 30 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 23 | 23 |
| Mri scan of blood flow of heart | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ezetimibe Other prescribers in St PAul, MN | 252 |
| Metoprolol Succinate Other prescribers in St PAul, MN | 173 |
| Atorvastatin Calcium Other prescribers in St PAul, MN | 121 |
| Eliquis (apixaban) Other prescribers in St PAul, MN | 106 |
| Losartan Potassium Other prescribers in St PAul, MN | 100 |
| Amlodipine Besylate Other prescribers in St PAul, MN | 95 |
| Rosuvastatin Calcium Other prescribers in St PAul, MN | 93 |
| Spironolactone Other prescribers in St PAul, MN | 50 |
| Jardiance (empagliflozin) Other prescribers in St PAul, MN | 47 |
| Vyndamax (tafamidis) | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $37,276 in research payments for these studies, mostly to the institutions running them.
- Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
Boehringer Ingelheim Pharma GmbH & Co.kg - EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.